Clinical trial
A Phase 2 Study to Assess the Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
NCT06344052 is registered in ClinicalTrials.gov with Stamford Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Assess the Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
- Lead sponsor
- Stamford Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 9, 2024
- Completion date
- March 30, 2029
- Enrollment
- 80 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.